MEDICINES CONTROL COUNCIL
|
|
|
- Damon O’Neal’
- 6 years ago
- Views:
Transcription
1 MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 47/26/0920 SANOFI-AVENTIS SA 47/26/0919 SANOFI-AVENTIS SA ZALTRAP 200 mg/8 ml ZALTRAP 100 mg/4 ml 47/26/0918 WINTHROP ZALZEN 200 mg/8 ml 47/26/0917 WINTHROP ZALZEN 100 mg/4 ml 46/2.6.5/0085 SPECPHARM SPEC QUETIAPINE /2.6.5/0084 SPECPHARM SPEC QUETIAPINE /2.6.5/0083 SPECPHARM SPEC QUETIAPINE /2.6.5/0082 SPECPHARM SPEC QUETIAPINE 100 AFLIBERCEPT 200,0 mg AFLIBERCEPT AFLIBERCEPT 200,0 mg AFLIBERCEPT 300,0 mg 200,0 mg 1 46/2.6.5/0081 SPECPHARM SPEC QUETIAPINE 25 45/21.2/0669 MYLAN MYLAN METFORMIN mg METFORMIN HYDROCHLORIDE 1 000,0 mg 12.78_Notification_of Apr14_v1 April 2014 Page 1 of 5
2 43/7.1.5/0984 LASARA TRADERS (PTY) 43/7.1.5/0983 LASARA TRADERS (PTY) 43/7.1.5/0982 LASARA TRADERS (PTY) 43/7.1.5/0981 LASARA TRADERS (PTY) 43/7.1.5/0980 LASARA TRADERS (PTY) 43/7.1.5/0979 LASARA TRADERS (PTY) 43/5.10/0762 ARROW PHARMA SOUTH AFRICA 43/5.10/0761 ARROW PHARMA SOUTH AFRICA 43/1.2/0699 BIOTECH LABORATORIES (PTY) 43/1.2/0698 BIOTECH LABORATORIES (PTY) VITRIXA 100 VITRIXA 50 VITRIXA 25 VIDENA 100 VIDENA 50 VIDENA 25 ENTRAN INJECTION 4 mg/2 ml ARROW INJECTION 4 mg/2 ml BIOTECH TRAZODONE 100 BIOTECH TRAZODONE 50 43/20.1.1/0238 SANDOZ SA SANDOZ LEVOFLOXACIN 500 mg/100 ml 43/20.1.1/0233 SANDOZ SA SANDOZ LEVOFLOXACIN 250 mg/50 ml 43/20.1.1/0232 SANDOZ SA LEVONIC 500 mg/100 ml HYDROCHLORIDE DIHYDRATE 4,0 mg HYDROCHLORIDE DIHYDRATE 4,0 mg TRASODONE HYDROCHLORIDE TRAZODONE HYDROCHLORIDE LEVOFLOXACIN 500,0 mg LEVOFLOXACIN 2 LEVOFLOXACIN 500,0 mg 43/20.1.1/0231 SANDOZ SA LEVONIC 250 mg/50 ml LEVOFLOXACIN 2 36/28/0137 BAYER ULTRAVIST ml Each 1,0 ml solution contains: IOPROMIDE IODINE 240,0 mg 12.78_Notification_of Apr14_v1 April 2014 Page 2 of 5
3 A40/32.5/0648 PHARMAFRICA HYLO-MAX EYE DROPS SOLUTION 46/20.2.8/0038 INGELHEIM 46/20.2.8/0037 INGELHEIM 45/5.2/0791 AUROBINDO PHARMA 45/5.2/0790 AUROBINDO PHARMA 45/5.2/0789 AUROBINDO PHARMA 45/20.2.3/0518 PHARMA DYNAMICS 44/8.2/1041 ASTRA ZENECA 43/20.2.8/0355 CIPLA LIFE SCIENCES 43/20.2.8/0353 CIPLA MEDPRO (PTY) 43/20.2.8/0226 INGELHEIM 41/7.5/0617 ARROW PHARMA SOUTH AFRICA 34/2.7/0290 RECKITT BENCKISER HEALTHCARE (SA) (PTY) ALVIR 50 mg/5 ml ALVIR 200 mg TABLETS BISBETA 10 mg BISBETA 5 mg BISBETA 2,5 mg DYNA ETHAMBUTOL 400 mg BRILINTA CIPLA EMTRICITABINE MEDPRO EMTRICITABINE 200 mg APTIVUS 250 mg BIOVAC SIMVASTATIN 80 mg IBUPROFEN RECKITT 200 Each 1,0 ml solution contains: SODIUM HYALURONATE 1,0 mg Each 5,0 ml suspension contains: NEVIRAPINE NEVIRAPINE 200,0 mg 10,0 mg 5,0 mg 2,5 mg ETHAMBUTOL HYDROCHLORIDE 400,0 mg TICAGRELOR 90,0 mg EMTRICITABINE 200,0 mg EMTRICITABINE 200,0 mg TIPRANAVIR 2 SIMVASTATIN 80,0 mg IBUPROFEN LYSINE equivalent to IBUPROFEN 200,0 mg A04/2.9/12 VIRBAC RSA SEDAXYLAN Each 1,0 ml solution contains: XYLAZINE HYDROCHLORIDE XYLAZINE 20,0 mg 45/11.4.3/0777 ASTRAZENECA 45/7.1.3/0626 ARROW PHARMA SOUTH AFRICA 45/7.1.3/0625 ARROW PHARMA SOUTH AFRICA 45/7.1.3/0624 ARROW PHARMA SOUTH AFRICA TRUSTAN 20 mg ESOMEPRAZOLE MAGNESIUM TRIHYDRATE ESOMEPRAZOLE 20,0 mg IRBESARTAN 300,0 mg IRBESARTAN 1 IRBESARTAN 75,0 mg 12.78_Notification_of Apr14_v1 April 2014 Page 3 of 5
4 45/7.1.3/0623 ARROW PHARMA SOUTH AFRICA 45/7.1.3/0622 ARROW PHARMA SOUTH AFRICA 45/7.1.3/0621 ARROW PHARMA SOUTH AFRICA 44/20.2.8/0016 BLISS cc 44/20.2.8/0015 BLISS cc 43/7.1.3/0445 ZYDUS HEALTHCARE SA 43/7.1.3/0444 ZYDUS HEALTHCARE SA 43/7.1.3/0443 ZYDUS HEALTHCARE SA 43/3.2/0132 WINTHROP 43/3.2/0131 WINTHROP 42/7.1.3/0094 AKACIA HEALTHCARE 42/7.1.3/0095 AKACIA HEALTHCARE 42/7.1.3/0096 AKACIA HEALTHCARE 42/7.1.3/0097 AKACIA HEALTHCARE 45/11.4.3/0778 ASTRAZENECA AROTAN 300 AROTAN 150 AROTAN 75 VORIOR HEVITREX 40 mg 20 mg 10 mg RISEDRONATE WINTHROP MONTHLY ACTONEL ONCE-A- MONTH LOZAAN 12,5 mg LOZAAN 25 mg LOZAAN 50 mg LOZAAN 100 mg TRUSTAN 40 mg IRBESARTAN 300,0 mg IRBESARTAN 1 IRBESARTAN 75,0 mg VALACICLOVIR 500,0 mg VALACICLOVIR 500,0 mg QUINAPRIL 40,0 mg QUINAPRIL 20,0 mg QUINAPRIL 10,0 mg RISEDRONATE SODIUM RISEDRONIC ACID 1 RISEDRONATE SODIUM RISEDRONIC ACID 1 12,5 mg ESOMEPRAZOLE MAGNESIUM TRIHYDRATE ESOMEPRAZOLE 40,0 mg 12.78_Notification_of Apr14_v1 April 2014 Page 4 of 5
5 45/30.1/0827 NOVARTIS SOUTH AFRICA MENVEO Each 0,5 ml solution contains: MENINGOCOCCAL GROUP A 10,0 ug MENINGOCOCCAL GROUP C MENINGOCOCCAL GROUP W MENINGOCOCCAL GROUP Y MS M HELA REGISTRAR OF MEDICINES 12.78_Notification_of Apr14_v1 April 2014 Page 5 of 5
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 36/20.1.2/0204 BIOTECH 36/20.1.2/0205
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 42/2.5/0453 ZYDUS HEALTHCARE
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 06/17.1.6/07 AFRIVET LOGISTICS
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 08/3.1.2/14 INGELHEIM A39/34/0605
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 41/20.1.1/0039 SCP MYLAN
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 07/3.1.2.2/23 NOVARTIS SA
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) A05/11.5/08 A38/20.1.1/0406
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 36/7.5/0281 PHARMACARE LIMITED
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 08/5.1/09 INGELHEIM 08/5.1/10
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 30/2.10/0392 TEVA TEVA BACLOFEN
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 26 July 2011 No. 4761
GOVERNMENT GAZETTE OF THE REPUBLIC OF N$4.00 WINDHOEK - 26 July 2011 No. 4761 CONTENTS Page GOVERNMENT NOTICE No. 122 Registration of certain medicines: Medicines and Related Substances Control Act, 2003...
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$2.00 WINDHOEK - 3 June 2011 No. 4726
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$2.00 WINDHOEK - 3 June 2011 No. 4726 CONTENTS Page GOVERNMENT NOTICE No. 71 Medicines and Related Substances Control Act, 2003: Registration of certain medicines...
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs CADUET (amlodipine besylate/atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 14 August 2013 No. 5263
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$4.00 WINDHOEK - 14 August 2013 No. 5263 CONTENTS Page GOVERNMENT NOTICES No. 211 No. 212 Request for submission of name of pharmacist for nomination for
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$5.60 WINDHOEK - 31 July 2012 No. 5003
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$5.60 WINDHOEK - 31 July 2012 No. 5003 CONTENTS Page GOVERNMENT NOTICES No. 186 Cancellation of certain medicines: Medicines and Related Substances Control
As a result of these reviews, Discovery Health has updated its Chronic Medicine Formulary and CDA.
Dear Pharmacist Update on the CDL formulary and Chronic Drug Amount for 2017 Discovery Health reviews the Chronic Medicine Formulary and Chronic Drug Amounts (CDAs) twice a year. We do this to make sure
NBPDP Formulary Update
Bulletin # 830 April 4, 2012 NBPDP Formulary Update Please find attached lists of interchangeable product additions to the New Brunswick Prescription Drug Program Formulary and non-listed products subject
New/Revised Product Name Section Changed
New/Revised Product Name Section Changed New Abisart New Agiolax New Apo-Ramipril Capsules New Calogen Extra New Candesartan HCTZ-GA New Candesartan-GA New Chemmart Metformin XR New Cholesterol Module
DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY
tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST tlo_seledyn.pdf 1 22.08.2017 14:38:01 PRODUCT NAME PHARMACEUTICAL FORM STRENGTH REFERENCE THERAPEUTIC CLASS ALIMENTARY TRACT & METABOLISM
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 26 February 2013 No. 5142
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$4.00 WINDHOEK - 26 February 2013 No. 5142 CONTENTS Page GOVERNMENT NOTICES No. 30 Notification of registration of certain medicines: Medicines and Related
AVAILABLE DOSSIERS. Product name Pharmaceutical form Strength Reference Therapeutic class
DOSSIER LIST AVAILABLE DOSSIERS Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM Esomeprazole sodium Omeprazole sodium injection / 40 mg Nexium / AstraZeneca
DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY
tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST AVAILABLE DOSSIERS THERAPEUTIC CLASS / MAIN INDICATION LACTOSE FREE ZONE IV CPP FEASIBILITY ALIMENTARY TRACT & METABOLISM 1. Esomeprazole
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs ZOLOFT (sertraline hydrochloride) tablets, for oral use This list does not imply that the products on this chart are interchangeable or have the
PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6
Abiraterone Tablet 250 mg Q4 2016 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Available Alendronic Acid Tablet 70 mg Available Amikacin Solution for injection 50 mg/ml; 125mg/ml;
Information for Vermont Prescribers of Prescription Drugs Long Form
Information for Vermont Prescribers of Prescription Drugs Long Form Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) Capsules The prices listed below are Average Wholesale
PROFESSIONAL INFORMATION
This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. SCHEDULING STATUS: Unscheduled: Complementary Medicine PROPRIETARY NAME AND DOSAGE FORM: BEROCCA
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
CONTACT POLPHARMA GROUP POLPHARMA B2B
DOSSIER FDFLIST Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM 1. Esomeprazole sodium or injection 40 mg Nexium / AstraZeneca Antiulcerant 2. Omeprazole
Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada,
1 Appendix Commentary 515 Appendix: Assessing Canada s Drug Shortage Problem Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada, 2013 16 Drug Name Dosage Therapeutic
DT Description Price Category Price change
Tariff T Watch October 2014 Readers are no doubt aware of this quarter's bad news for primary care prescribing allocations: NHS England has d the remuneration mechanism for community pharmacies gaining
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs ARTHROTEC (diclofenac sodium/misoprostol) tablets This list does not imply that the products on this chart are interchangeable or have the same
PORTFOLIO Q June 2014 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/5
Abiraterone Tablet 250 mg Q4 2015 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Q4 2014 Alendronic Acid Tablet 70 mg Available Amisulpride Tablet 50 ; 100 ; 200 ; 400 mg Available
Information for Vermont Prescribers of Prescription Drugs. Lunesta (eszopiclone tablets)
Information for Vermont Prescribers of Prescription Drugs Lunesta (eszopiclone tablets) This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety.
Recommended comparator products: Medicines for HIV/AIDS and related diseases
Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal
NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)
HUMAN DRUGS NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 COMPANY BRAND NAME CHEMICAL NAME DIN THERAPEUTIC USE DATE OF FIRST SALE Abbott Laboratories Limited Norvir 100 mg/tablet ritonavir 02357593 HIV
SOLID DOSAGE FORMULATIONS
SOLID DOSAGE FORMULATIONS Jubilant Generics, is one of the business arms of J Jubilant Pharma Group, catering to Dosage Formulations (DF) & Active Pharmaceutical Ingredients (API) business segment across
PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs ARTHROTEC (diclofenac sodium/misoprostol) tablets This list does not imply that the products on this chart are interchangeable or have the same
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference.
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference. Product Number API Test product Dose/ mg Manufacturer Country of manufacture Country
LETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
Latest Gazetted Regulations and Guidelines : SMASA Concerns/Comments
THE SELF MEDICATION MANUFACTURERS ASSOCIATION OF SOUTH AFRICA (SMASA) Latest Gazetted Regulations and Guidelines : SMASA Concerns/Comments Dr Deepa Maharaj Chair Technical & Regulatory Committee SAPRAA
DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %
June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has
Award of Contracts without Competition December 2013
SERIVCES 2850 Open Text Opentext Web CMS Software Support 125,000.00 Business Services Organisation 2259 Lynas Cooked Pork (Lynas) 63,063.00 2703 Limavady Office Products 169,477.00 2817 Merck no 3 Nutritional
REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
Price Changes advised by Pharmac As at 12 June 2015
s advised by Pharmac New to be available ex Manufacturer from 12th of preceding month. From Wholesale from date of supplier support which could vary. Product Supplier Schedule % + or - 01 Jun 15 31 Oct
Information for Vermont Prescribers of Prescription Drugs Tradjenta (linagliptin) and Jentadueto (linagliptin+metformin) Tablets
Information for Vermont Prescribers of Prescription Drugs Tradjenta (linagliptin) and Jentadueto (linagliptin+metformin) Tablets This list does not imply that the products on this chart are interchangeable
PROFESSIONAL INFORMATION
This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. SCHEDULING STATUS: Unscheduled (Complementary medicine) PROPRIETARY NAME AND DOSAGE FORM: BEROCCA
2018 Step Therapy Criteria
2018 Step Therapy Criteria ANGIOTENSIN RECEPTOR BLOCKERS... 2 ANTIDEPRESSANTS... 3 ANTIDEPRESSANTS, MISCELLANEOUS... 4 ANTIDEPRESSANTS, OTHER... 5 ANTIDIABETIC AGENTS... 6 ANTIGOUT AGENTS... 7 ANTIHYPERTENSIVE
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS
ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18
Legal Supplement Part B Vol. 57, No. 6 18th January, NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS
Legal Supplement Part B Vol. 57, No. 6 18th January, 2018 11 LEGAL NOTICE NO. 5 REPUBLIC OF TRINIDAD AND TOBAGO FOOD AND DRUGS ACT, CHAP. 30:01 NOTIFICATION NOTICE OF APPROVAL IN RESPECT OF NEW DRUGS ISSUED
J Jubilant Pharma Group, catering to Dosage
DOSAGE FORMULATIONS Jubilant Generics, is one of the business arms of J Jubilant Pharma Group, catering to Dosage Formulations (DF) & Active Pharmaceutical Ingredients (API) business segment across developed
COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH
1 Abacavir Sulphate Antiretroviral - * - 2 Abiraterone Acetate Oncology - - - 3 Albendazole Anti-infective - - - 4 Albuterol Sulphate Respiratory - - 5 Alendronate Sodium Trihydrate Metabolic Disorder
Artesunate/amodiaquine 100/270 mg WHOPAR part 5 03/2009, version 1.0 (Sanofi-Aventis) MA058 LABELING
LABELING 1 PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton box 25 blisters of 3 tablets 1. NAME OF THE MEDICINAL PRODUCT ARTESUNATE AMODIAQUINE WINTHROP 100mg / 270mg Tablets* 2. STATEMENT OF ACTIVE
formulations Product List- row
Solid Dosage formulations Product List- row Therapy Products Strengths Innovator Brand Benazepril + HCTZ 5+ 6.25mg, 10+12.5mg, 20+12.5mg, 20+25mg Brand Name Lotensin HCT Company Validus Pharma Candesartan
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
LETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
Table 1: Price increases for Brand Name Drugs with Generic Equivalents
Table 1: Price increases for Brand Name Drugs with Generic Equivalents Brand Name Medication and Dose Total % Change Since 10/2012 ACTOS 15 MG TABLET 6.36 11.03 73.39% ACTOS 30 MG TABLET 9.7 16.80 73.23%
A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs
Pharmacy Benefact A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS Number 723 February 2018 Pan-Canadian Select Molecule Price Initiative for Generic Drugs Alberta Drug Benefit List prices
Decentralised Procedure. Public Assessment Report. Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC Applicant: Reckitt Benckiser Reference
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
Updates to the Alberta Drug Benefit List. Effective November 1, 2018
Updates to the Alberta Drug Benefit List Effective November 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules The prices listed below are Average Wholesale Prices ( AWP ) as established and made
Appendix K Declarations of Interests
Appendix K Declarations of Interests Ms Theresa Shaw - Chair, Guideline Development Group Chief Executive, Foundation of Nursing Studies (FoNS), London Funding for the 'Developing Practice for Healthy
History of Laminaria hyperborea resource management
Long history Feed, fertilizers, iodine production and soda production (soap). Alginate, carrageenan, and agar are used in a number of applications in food, pharmaceuticals, biomedical and technical products.
Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
RESULTS AND DISCUSSION
RESULTS AND DISCUSSION 203 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire
TLS HEALTH Product list up-dated 2017 (Origin: Portugal)
TLS HEALTH Product list up-dated 2017 (Origin: Portugal) 1 Alendronic acid 70 mg tablet 4 units 2 Amlodipine 10 mg tablet 20,60 units 3 Amlodipine 5 mg tablet 20,60 units 5 Aripiprazole 10 mg tablet 14,
SOLID DOSAGE FORMULATIONS
SOLID DOSAGE FORMULATIONS ubilant Generics, is one of the business arms of J Jubilant Pharma Group, catering to Dosage Formulations (DF) & Active Pharmaceutical Ingredients (API) business segment across
Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Saturday, October 27, 2018 7:00 AM - 3:45 PM Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer Program Director John V.
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
MRP Monthly Update MRP 12/2013
Monthly Update 12/2013 13/12/2013 Mediscor Reference Price - Notification Effective Date: 1 January 2014 Dear Vendors and Colleagues, The files for January 2014 are now available on our website: www.mediscor.net/mrp.html
NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order,
What s New 12.06.2018 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations
Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro
Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices
FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
TODAY LETTER DATED
TODAY LETTER DATED 26.06.2018 GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT.. 18670 PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY
Prequalification Programme Bioequivalence Assessment Update. Dr. John Gordon
Prequalification Programme Bioequivalence Assessment Update Dr. John Gordon WHO Prequalification of Medicines Programme 3 rd Meeting with Manufacturers of FPPs and APIs Overview Review of commonly used
OTCPharm FY/Q sales results
OTCPharm FY/Q4 2014 sales results Olga Mednikova, CEO Irina Bakhturina, Head of Investor Relations February, 2015 Russia Pharma Market Update In 2014, Russian commercial OTC market grew by 9.5% y-o-y reaching
Information for Vermont Prescribers of Prescription Drugs Long Form Bystolic (nebivolol) Tablets
Information for Vermont Prescribers of Prescription Drugs Long Form Bystolic (nebivolol) Tablets The prices listed below are Average Wholesale Prices ( AWP ) as established and made available to the public
Allergan s Blephamide (sulfacetamide/prednisolone ophthalmic ointment) 10%/0.2%, 3.5Gm tube
Allergan s Blephamide (sulfacetamide/prednisolone ophthalmic ointment) 10%/0.2%, 3.5Gm tube On Aug. 24, 2015, Allergan recalled three lots (86258 expires September 2017, 87189 December 2017 and 87514 February
Information for Vermont Prescribers of Prescription Drugs DUZALLO (lesinurad and allopurinol) Tablets
Information for Vermont Prescribers of Prescription Drugs DUZALLO (lesinurad and allopurinol) Tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy
Boston University Expert Review Meeting on the Evaluation of Novartis Access
Boston University Expert Review Meeting on the Evaluation of Novartis Access Principal Investigator: Richard Laing Co-investigators: Peter Rockers, Veronika Wirtz, Taryn Vian, Monica Onyango, Paul Ashigbie
Industry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
Read this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. If you have further questions, please ask your doctor or your pharmacist.
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNA BEZAFIBRATE 400 SR (slow release tablets) Read this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. Keep
Palliative Coverage Drug Benefit Supplement
Palliative Coverage Drug Benefit Supplement Effective April 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
The Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
Innovative Products Available. OTC Products Available
Innovative Products Benfotiamine film-coated tablets 150 mg Cholecalciferol film-coated tablets 22400 I.U. Diltiazem rectal ointment 2% Agents for Treatment of Hemorrhoids and Fissures Blood and Blood
TEPZZ A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 9/20 (2006.
(19) TEPZZ 96746A_T (11) EP 2 96 746 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 13.01.16 Bulletin 16/02 (1) Int Cl.: A61K 9/00 (06.01) A61K 9/ (06.01) (21) Application number: 102377.1
Systemic and inhaled fluoroquinolones: risk of aortic aneurysm and dissection
Direct Healthcare Professional Communication 23 rd October 2018 Systemic and inhaled fluoroquinolones: risk of aortic aneurysm and dissection Dear Healthcare Professional, The Marketing Authorisation Holders